TICKERNERD
Menu
OLMAOLMAHealthcare · Biotechnology

OLMA Stock Forecast: Olema Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$10
−4.40% on the day

The 12 Wall Street analysts covering Olema Pharmaceuticals, Inc. hold a median 12-month price target of $40 — +291.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$894.2M
Ticker Nerd rank
30 / 100
Median analyst target
$40
Analysts covering
12
Revenue$0.0
Operating income−$67.2M
Net income−$63.2M
Free cash flow−$46.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.8%
1M
−2.0%
YTD
−59.1%
1Y
+27.8%
From 52W high
−71.5%
From 52W low
+31.9%
$8
$36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OLMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Olema Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
63
Value
59
Quality
58
Size
46
Volatility
46
Accruals
39
Issuance
38
Revisions
27
Growth
24

Momentum (63): The shares have been drifting up relative to others.

Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OLMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OLMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26OLMAHigh $59Median $40Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $20Median $40High $59

The green dot is the last close — the median target sits +291.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
13 Aug 2026JP MorganMaintainsOverweight$52 → $46
11 Aug 2026CitigroupMaintainsBuy$62 → $59
11 Aug 2026HC Wainwright & Co.MaintainsBuy$38 → $36
13 May 2026GuggenheimMaintainsBuy$38 → $35
13 May 2026GuggenheimMaintainsBuy—
27 Mar 2026Wolfe ResearchInitiatesPeer Perform—
19 Mar 2026JefferiesAssumesBuy$43 → $40
18 Mar 2026Goldman SachsMaintainsBuy—
18 Mar 2026JP MorganMaintainsOverweight—
17 Mar 2026CitigroupMaintainsBuy—
17 Mar 2026GuggenheimMaintainsBuy—
9 Mar 2026HC Wainwright & Co.MaintainsBuy—
11 Feb 2026StifelInitiatesBuy—
7 Jan 2026Piper SandlerInitiatesOverweight—
7 Jan 2026UBSInitiatesBuy—
12 Dec 2025CitigroupMaintainsBuy—
11 Dec 2025Goldman SachsMaintainsBuy—
11 Dec 2025HC Wainwright & Co.MaintainsBuy—
11 Dec 2025OppenheimerMaintainsOutperform—
21 Nov 2025Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OLMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OLMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Olema Pharmaceuticals, Inc. returned +27.8% against +17.5% for the S&P 500, dividends included.

OLMA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Oct 25Jan 26Apr 26Jul 26OLMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OLMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
7
Fundamentals

Olema Pharmaceuticals, Inc. (OLMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 44% of US stocks

EV / EBITDA
−2.0×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−52.7%

Higher than 21% of US stocks

Return on assets
−31.8%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Olema Pharmaceuticals, Inc. (OLMA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Olema Pharmaceuticals, Inc. has a market value of $894.2M and an enterprise value of $436.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$204.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$165.0M.

  • Shares outstanding: 87.5M.

  • Trailing P/E: −5.5×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Olema Pharmaceuticals, Inc. employs 150 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

OLMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OLMAOlema Pharmaceuticals, Inc.$894.2M
30
LXRXLexicon Pharmaceuticals, Inc.$889.9M
68
WVEWave Life Sciences, Inc.$883.0M
14
DSGNDesign Therapeutics, Inc.$902.3M
65
RIGLRigel Pharmaceuticals, Inc.$874.0M
77
ARDXArdelyx, Inc.$869.8M
50
SLDBSolid Biosciences, Inc.$914.6M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Olema Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OLMA news & analysis

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Olema Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. No specific details from the presentation are provided in the excerpt.

Why it matters — A company presentation at a major investment summit offers Olema watchers insight into management's latest messaging and business updates.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Sept 2026neutral

Olema Pharmaceuticals announced it granted its newly appointed Chief Financial Officer, Jason V. O'Byrne, an employment inducement award of stock options to purchase 650,000 shares of common stock, with an exercise price of $10.56 per share and a grant date of September 1, 2026. The award was approved by the Compensation Committee and issued under the company's 2022 Inducement Plan, vesting over four years subject to continued employment.

Why it matters — The inducement grant signals the company's executive leadership transition and aligns the new CFO's compensation with long-term shareholder value via equity vesting over four years.

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewsWire · 31 Aug 2026neutral

Olema Oncology announced it will participate in several upcoming investor conferences. The clinical-stage biopharmaceutical company, focused on targeted therapies for breast cancer, did not disclose specific details in the announcement.

Why it matters — Participation in investor conferences may give Olema Oncology the opportunity to present its pipeline and update investors on its progress.

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Benzinga · 11 Aug 2026negative

Olema Pharmaceuticals completed enrollment in its pivotal Phase 3 OPERA-01 breast cancer trial, with top-line data now expected in the first quarter of 2027. Shares traded lower on Tuesday following the announcement.

Why it matters — The delayed timeline for the OPERA-01 pivotal trial results extends the wait for a key clinical catalyst for Olema, a factor that would weigh on investor expectations.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Aug 2026neutral

Olema Pharmaceuticals granted stock options to seven new employees for an aggregate of 254,540 shares of common stock, effective August 3, 2026, under the company's 2022 Inducement Plan. The awards were approved by the Compensation Committee and granted as an inducement material to the new employees joining Olema, per Nasdaq Listing Rule 5635(c)(4).

Why it matters — The stock-option grants signal continued hiring activity at the clinical-stage company, which may reflect progress in its pipeline but also results in potential dilution for existing shareholders.

FAQ

Frequently asked questions about OLMA stock

What is the OLMA stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Olema Pharmaceuticals, Inc. have a median 12-month price target of $40, with estimates ranging from $20 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OLMA stock a buy right now?

Of the 12 analysts covering Olema Pharmaceuticals, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Olema Pharmaceuticals, Inc. 30 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OLMA?

As at 12 Sept 2026, Olema Pharmaceuticals, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (63 of 100).

Will OLMA stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +291.4% from the last close, and Ticker Nerd's factor model ranks Olema Pharmaceuticals, Inc. 30 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OLMA stock forecast for 2030?

No analyst covering Olema Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OLMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $59 over the next 12 months.

How has OLMA stock performed over the past year?

Olema Pharmaceuticals, Inc. returned +27.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Olema Pharmaceuticals, Inc. do?

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with a primary emphasis on breast cancer.

What is the latest news on OLMA?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Olema Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. No specific details from the presentation are provided in the excerpt.

Company

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with a primary emphasis on breast cancer. The company’s current pipeline centers on palazestrant (OP-1250), an oral estrogen receptor antagonist and selective estrogen receptor degrader being studied for hormone receptor-positive breast cancer, and OP-3136, a KAT6 inhibitor in early clinical development. Olema’s research is built around endocrine-driven cancers and mechanisms of acquired resistance, reflecting a focus on precision oncology approaches for difficult-to-treat disease settings. The company is headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. Olema Pharmaceuticals, Inc. plays a specialized role in the biotechnology market as a development-stage oncology company advancing novel medicines for breast cancer and related women’s cancers.

CEO Dr. Sean P. Bohen M.D., Ph.D. · 150 employees · United States · https://olema.com